fosfestrol and Carcinoma--Signet-Ring-Cell

fosfestrol has been researched along with Carcinoma--Signet-Ring-Cell* in 1 studies

Other Studies

1 other study(ies) available for fosfestrol and Carcinoma--Signet-Ring-Cell

Article	Year
Locally-confined signet-ring cell carcinoma of the prostate: a case report of a long-term survivor. International journal of urology : official journal of the Japanese Urological Association, 1996, Volume: 3, Issue:5 It is generally believed that signet-ring cell carcinoma (SRCC) of the prostate is a high-grade neoplasm with a poor prognosis. We report a case of a long-term survivor diagnosed with localized prostatic SRCC (T3N0M0), who has been alive without any clinical evidence of disease for 100 months after combination therapy which consisted of local irradiation and hormone administration. A posttreatment needle biopsy confirmed the pathological complete response. Topics: Administration, Oral; Aged; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Signet Ring Cell; Diethylstilbestrol; Disease-Free Survival; Humans; Immunohistochemistry; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant	1996

Article

Year

Locally-confined signet-ring cell carcinoma of the prostate: a case report of a long-term survivor.

International journal of urology : official journal of the Japanese Urological Association, 1996, Volume: 3, Issue:5

It is generally believed that signet-ring cell carcinoma (SRCC) of the prostate is a high-grade neoplasm with a poor prognosis. We report a case of a long-term survivor diagnosed with localized prostatic SRCC (T3N0M0), who has been alive without any clinical evidence of disease for 100 months after combination therapy which consisted of local irradiation and hormone administration. A posttreatment needle biopsy confirmed the pathological complete response.

Topics: Administration, Oral; Aged; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Signet Ring Cell; Diethylstilbestrol; Disease-Free Survival; Humans; Immunohistochemistry; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant

1996